secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adverum Biotechnologies, Inc. (—)
CIK:        0001501756
Form:       8-K
Filed at:   2025-12-09T23:59:59+00:00
Accession:  0001193125-25-312722
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Adverum Biotech acquired by Eli Lilly; tender offer closes, merger completed
----------------------------------------------------------------------------

- 64% of shares tendered; $3.56/share cash plus CVRs worth up to $8.91/share.
- Merger completed under DGCL Section 251(h); Adverum becomes wholly owned Lilly subsidiary.
- All incumbent directors and officers removed; new board and officers from Lilly appointed.
- Shares to be delisted from Nasdaq and registration terminated under SEC Form 25 and Form 15.
- Company charter and bylaws amended and restated effective at merger close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/0001193125-25-312722-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501756/000119312525312722/d96637d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-312722

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer